Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Invested Capital (2020 - 2024)

Immuneering has reported Invested Capital over the past 5 years, most recently at $57.7 million for Q3 2024.

  • Quarterly results put Invested Capital at $57.7 million for Q3 2024, down 44.51% from a year ago — trailing twelve months through Sep 2024 was $57.7 million (down 44.51% YoY), and the annual figure for FY2023 was $90.6 million, down 17.55%.
  • Invested Capital for Q3 2024 was $57.7 million at Immuneering, down from $66.3 million in the prior quarter.
  • Over the last five years, Invested Capital for IMRX hit a ceiling of $158.3 million in Q3 2021 and a floor of -$35.2 million in Q2 2021.
  • Median Invested Capital over the past 5 years was $94.2 million (2023), compared with a mean of $73.2 million.
  • Peak annual rise in Invested Capital hit 1038.75% in 2021, while the deepest fall reached 175.46% in 2021.
  • Immuneering's Invested Capital stood at -$22.5 million in 2020, then soared by 793.82% to $156.0 million in 2021, then decreased by 29.57% to $109.9 million in 2022, then fell by 17.55% to $90.6 million in 2023, then tumbled by 36.27% to $57.7 million in 2024.
  • The last three reported values for Invested Capital were $57.7 million (Q3 2024), $66.3 million (Q2 2024), and $78.7 million (Q1 2024) per Business Quant data.